


## FX-909

<b>Cat. No.:</b>	HY-153344		
<b>CAS No.:</b>	2924573-90-8		
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>10</sub> F <sub>2</sub> N <sub>2</sub> O <sub>3</sub> S		
<b>Molecular Weight:</b>	360.33		
<b>Target:</b>	PPAR		
<b>Pathway:</b>	Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (277.52 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
<b>Preparing Stock Solutions</b>	1 mM	2.7752 mL	13.8762 mL	27.7523 mL
	5 mM	0.5550 mL	2.7752 mL	5.5505 mL
	10 mM	0.2775 mL	1.3876 mL	2.7752 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.94 mM); Clear solution			

## BIOLOGICAL ACTIVITY

<b>Description</b>	FX-909 is a covalent peroxisome proliferator-activated receptor gamma (PPARG) inverse agonist. FX-909 can be used for the research of cancer <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	PPAR $\gamma$
<b>In Vivo</b>	FX-909 (0.03-1 mg/kg; BID for 21 days) shows anticancer effects in UMUC9 UC xenograft mouse model <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

---

[1]. Mertz J A, et al. Development of a surrogate tissue pharmacodynamic (PD) assay for clinical use with FX-909, a novel inhibitor of the urothelial luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG). *Cancer Research*, 2023, 83(7\_Supplement): 2802-2802.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA